- Home
- BCSF vs SGP Comparison
BCSF vs SGP Comparison
Compare BCSF & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | SGP |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.5M | 932.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCSF | SGP |
|---|---|---|
| Price | $13.40 | $23.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 331.2K | 49.1K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 14.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $270.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $20.15 |
| 52 Week High | $16.00 | $30.56 |
Technical Indicators
Market Signals| Indicator | BCSF | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 44.29 |
| Support Level | $13.33 | $20.95 |
| Resistance Level | $13.76 | $26.29 |
| Average True Range (ATR) | 0.35 | 1.47 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 20.25 | 38.44 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.